[go: up one dir, main page]

MX2011009277A - Composicion de leucocito activada. - Google Patents

Composicion de leucocito activada.

Info

Publication number
MX2011009277A
MX2011009277A MX2011009277A MX2011009277A MX2011009277A MX 2011009277 A MX2011009277 A MX 2011009277A MX 2011009277 A MX2011009277 A MX 2011009277A MX 2011009277 A MX2011009277 A MX 2011009277A MX 2011009277 A MX2011009277 A MX 2011009277A
Authority
MX
Mexico
Prior art keywords
activated leukocyte
leukocyte composition
methods
compositions
composition
Prior art date
Application number
MX2011009277A
Other languages
English (en)
Inventor
Mitchell Shirvan
Eilat Shinar
Orit Frenkel
Adi Zuloff-Shani
Marina Bubis
Eilat Bain
Irene Ginis
Original Assignee
Macrocure Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrocure Ltd filed Critical Macrocure Ltd
Publication of MX2011009277A publication Critical patent/MX2011009277A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0057—Ingredients of undetermined constitution or reaction products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0642—Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Materials Engineering (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se divulgan composiciones de leucocito activadas, derivadas de la sangre, terapéuticas, métodos para hacerlas, y métodos para usar las composiciones para reparar o promover la sanación de heridas.
MX2011009277A 2009-03-05 2010-03-05 Composicion de leucocito activada. MX2011009277A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20929809P 2009-03-05 2009-03-05
US21158709P 2009-04-01 2009-04-01
PCT/IB2010/000882 WO2010100570A2 (en) 2009-03-05 2010-03-05 Activated leukocyte composition

Publications (1)

Publication Number Publication Date
MX2011009277A true MX2011009277A (es) 2011-12-16

Family

ID=42710060

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011009277A MX2011009277A (es) 2009-03-05 2010-03-05 Composicion de leucocito activada.

Country Status (15)

Country Link
EP (2) EP2650001B1 (es)
JP (2) JP5713924B2 (es)
KR (1) KR101548783B1 (es)
CN (1) CN102438635B (es)
AU (1) AU2010220132B2 (es)
BR (1) BRPI1006759A2 (es)
CA (2) CA2867976A1 (es)
DK (1) DK2403509T3 (es)
ES (1) ES2428102T3 (es)
IL (1) IL214953A0 (es)
MX (1) MX2011009277A (es)
PL (1) PL2403509T3 (es)
RU (2) RU2548741C2 (es)
WO (1) WO2010100570A2 (es)
ZA (1) ZA201107269B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8574902B2 (en) 2009-03-05 2013-11-05 Macrocure Ltd. Activated leukocyte composition and uses for wound healing
CA2810629A1 (en) 2010-09-09 2012-03-15 Macrocure, Ltd. Activated leukocyte conditioned supernatant and uses for wound healing
US20150030635A1 (en) 2012-03-15 2015-01-29 Macrocure, Ltd. Activated Immunostimulatory Cell Composition and Uses Thereof
EP2825182A1 (en) 2012-03-15 2015-01-21 Macrocure, Ltd. Activated immunostimulatory cell composition for therapy of infection
EP2781224A1 (en) 2013-03-18 2014-09-24 Khorionyx Implantable preparations comrpsing globin insoluble at physiological pH and serum for regeneration of tissues and treatment of wounds.
CN107427535A (zh) 2015-02-16 2017-12-01 纳雅康医疗有限公司 经修饰的血凝块
GB201618106D0 (en) 2016-10-26 2016-12-07 Lift Biosciences Ltd Cancer-killing cells

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60120821A (ja) * 1983-12-05 1985-06-28 Asahi Chem Ind Co Ltd 悪性腫瘍治療用白血球刺激材および刺激方法
US4751001A (en) * 1984-09-24 1988-06-14 Becton Dickinson And Company Blood partitioning apparatus
JPH02167071A (ja) * 1988-12-19 1990-06-27 Terumo Corp 非ヒト動物由来白血球系細胞の分離材、分離器および分離方法
JPH07102151B2 (ja) * 1994-06-03 1995-11-08 中外製薬株式会社 新規なポリペプチドの製造法
US6146890A (en) * 1994-07-03 2000-11-14 Danon; David Method and system for cultivating macrophages
IL110195A (en) * 1994-07-03 2003-10-31 David Danon Method and system for cultivating macrophages
JP3201610B2 (ja) * 1995-03-17 2001-08-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 腫瘍を処置する方法
JPH10259134A (ja) * 1997-01-16 1998-09-29 Sekisui Chem Co Ltd 創傷治癒促進剤
RU2143685C1 (ru) * 1998-05-19 1999-12-27 Коган Александр Харитонович Способ дифференциального подсчета гранулоцитов, моноцитов и лимфоцитов
DE69941498D1 (de) * 1998-11-12 2009-11-12 Internat Mfg Group Inc Hämostatische vernetzte Dextranperlen verwendbar zur schnellen Blutgerinnung und Hämostase
US8377692B2 (en) * 2001-11-21 2013-02-19 Yeda Research And Development Co., Ltd. Process for the manufacturing of human mononuclear phagocytic leukocytes
JP4108393B2 (ja) * 2002-07-15 2008-06-25 テルモ株式会社 細胞増殖剤の製造方法
JP4245324B2 (ja) * 2002-10-09 2009-03-25 旭化成クラレメディカル株式会社 単球の分離回収方法
EP2198873A1 (en) * 2008-12-18 2010-06-23 Aposcience AG Pharmaceutical preparation comprising supernatant of blood mononuclear cell culture
EP2201954A1 (en) * 2008-12-18 2010-06-30 Aposcience AG Pharmaceutical preparation

Also Published As

Publication number Publication date
DK2403509T3 (da) 2013-09-16
KR101548783B1 (ko) 2015-08-31
CA2754190A1 (en) 2010-09-10
AU2010220132A1 (en) 2011-10-13
RU2015102067A (ru) 2015-06-20
AU2010220132B2 (en) 2013-10-10
JP2012519681A (ja) 2012-08-30
CA2867976A1 (en) 2010-09-10
WO2010100570A2 (en) 2010-09-10
PL2403509T3 (pl) 2013-11-29
RU2011139016A (ru) 2013-04-10
JP5713924B2 (ja) 2015-05-07
EP2650001B1 (en) 2016-09-07
BRPI1006759A2 (pt) 2016-03-15
ZA201107269B (en) 2014-03-26
RU2548741C2 (ru) 2015-04-20
KR20120002530A (ko) 2012-01-05
EP2403509B1 (en) 2013-08-21
CN102438635B (zh) 2014-09-17
WO2010100570A3 (en) 2010-12-16
ES2428102T3 (es) 2013-11-05
CN102438635A (zh) 2012-05-02
JP2015129180A (ja) 2015-07-16
EP2403509A2 (en) 2012-01-11
EP2650001A1 (en) 2013-10-16
IL214953A0 (en) 2011-11-30

Similar Documents

Publication Publication Date Title
MY164356A (en) Substituted 5-fluoro-1h-pyrazolopyridines and their use
TN2009000132A1 (en) Substituted dihydropyrazolones for treating cardiovascular and haematological diseases
BRPI0917017B8 (pt) inibidores de pirrol de s-nitrosoglutationa redutase como agentes terapêuticos
CU20140141A7 (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas
IN2012DN00971A (es)
WO2012088266A3 (en) Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
TW201129377A (en) Binding proteins that bind to human FGFR1c, human β-Klotho and both human FGFR1c and human β-Klotho
DE602007010764D1 (en) Benzamidglucokinaseaktivatoren
MX2019000225A (es) Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.
MX2012000396A (es) Metodos y composiciones para uso en tartamientos celulares.
PH12012501838A1 (en) Aptamers to ãŸ-ngf and their use in treating ãŸ-ngf mediated diseases and disorders
EA201001639A1 (ru) Композиции и способы их получения и применения
MX2011011768A (es) Composiciones y metodos de uso para moleculas de enlace a dickkopf-1 o dickkopf-4 o a ambos.
MX2012000434A (es) Metodo de sanacion de herida y modulacion de cicatriz.
MX343135B (es) Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
IN2014DN06104A (es)
UA102432C2 (ru) Цитотоксичные конъюгаты с соединением, которое связывает рецептор нейропептиду y
MX2011009277A (es) Composicion de leucocito activada.
WO2009114703A3 (en) Combination therapy for the treatment of cancer
IL207310A0 (en) Vaccine compositions
UA107204C2 (uk) Протигрибкова композиція, що містить грибковий організм pythium oligandrum
WO2011100330A3 (en) Compositions and methods for preventing or treating a human parvovirus infection
MX2013002539A (es) Sobrenadante condicionado por leucocitos activados y usos para la cicatrizacion de heridas.
MX2013002261A (es) N-fenetiltriazolonacetamidas sustituidas y su uso.
EP2597949A4 (en) SUBMIKROMETERZUSAMMENSETZUNGEN

Legal Events

Date Code Title Description
FG Grant or registration